4Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：60
6Jeffrey S. Berger,Maria C. Roncaglioni,Fausto Avanzini,Ierta Pangrazzi,Gianni Tognoni,David L. Brown,崔艳丽（译）,赵秀丽（校）.阿斯匹林在男性和女性心血管事件一级预防中的应用——随机对照试验性别特异性汇总分析[J].美国医学会杂志（中文版）,2006,25(5):275-282. 被引量：40
4Serebruany VL,Steinhubi SR,Berger PB,et al.Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.Am J Cardio1,2005,95:1218-1222.
5Walker J,Robinson J,Stewart J,et al.Does enteric-ccated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Stag,2007,6:519-522.
6Kelly JP,Kanfman DW,Jurgelon JM,et al.Risk of aspirinassociated major upper-gastrointestinal bleeding with enteric-coated or buffered product.Lancet,1996,348:1413-1416.
7Hemandez-Diaz S,Garcia Rodriguez LA.Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications.BMC Med,2006,4:22.
8Taha AS,Angerson WJ,Prnsad R,et al.Clinical trial:the incidence and early mortality after peptic ulcer perforation,and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs.Aliment Pharmacol Ther,2008,28:878-885.
9Papatheodoridis GV,Sougioultzis S,Archimandrifis AJ.Effcts of Helicobacter pylori and nonsteroidal anti-inflammatery drugs on peptic ulcer disease:a systematic review.Clin Gastroenterol Hepatol,2006,4:130-142.
10Huang JQ,Sridhar S,Hunt RH.Role of Helicobacter pylori infection and non-steroidal anti-infammatury drugs in peptic-ulcer disease:a meta-analysis.Lancet,2002,359:14-22.
